Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL

ASCO 2020: Results of a study investigating dual CD19 and CD20 CAR T therapies for treatment of relapsed B-cell lymphomas.